Millendo therapeutics, inc. (MLND)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating activities:
Net loss

-44,568

-27,177

-84,586

-

-

-

-

-

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

97

32

28

-

-

-

-

-

Stock-based compensation expense

4,317

1,427

762

-

-

-

-

-

Write-off of deferred financing costs

0

871

1,364

-

-

-

-

-

Non-cash interest

0

204

120

-

-

-

-

-

Amortization of right-of-use asset

955

-

-

-

-

-

-

-

Acquired in-process research and development

-

-

63,844

-

-

-

-

-

Change in fair value of preferred stock warrant liability

0

-40

-28

-

-

-

-

-

Other non-cash items

-30

0

-

-

-

-

-

-

Net loss

-

-

-

-82,260

-73,219

-49,520

-29,044

-13,510

Depreciation and amortization

-

-

-

2,238

1,286

450

231

93

Impairment of property and equipment

-

-

-

-

-

0

-

-

Impairment of property and equipment related to restructuring

-

-

-

1,994

0

0

-

-

Impairment of property and equipment

-

-

-

-

-

-

364

-

Amortization of (discount) premium on debt securities

-

-

-

659

1,116

871

586

77

Stock-based compensation expense

-

-

-

9,215

19,337

12,407

5,094

1,382

Issuance of common stock for director fees

-

-

-

154

165

-

-

-

Proceeds from Issuance or Sale of Equity

-

-

-

-

-

0

-

-

Issuance of common stock for technology access and other fees

-

-

-

-

-

-

2,500

-

Net loss on equity method investment

-

-

-

-

-

-1,583

0

-

Net loss on equity method investment

-

-

-

-1,542

-1,561

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

698

2,524

-1,002

-946

1,113

997

76

530

Other assets

-66

0

-

-

-

-

-

-

Accounts payable

-469

320

-1,452

-

-

-

-

-

Accounts payable

-

-

-

-1,178

-171

2,317

-721

599

Accrued expenses and other liabilities

281

3,240

-1,394

4,809

752

2,301

2,972

733

Operating lease liabilities

-1,233

-

-

-

-

-

-

-

Cash used in operating activities

-41,222

-23,647

-20,340

-61,734

-50,286

-30,588

-18,094

-

Investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-11,156

Investment in joint venture

-

-

-

-

-

1,500

0

-

Purchase of property and equipment

397

36

4

2,586

5,229

2,804

719

849

Proceeds from sale of marketable securities

4,385

2,492

-

-

-

-

-

-

Net cash paid in Alizé asset purchase

0

524

-462

-

-

-

-

-

Maturities of short-term investments

-

-

-

72,013

53,528

20,797

5,670

-

Proceeds from sale of property, plant and equipment

-

-

-

23,089

10,817

8,431

0

-

Purchases of short-term investments

-

-

-

82,671

95,225

57,603

15,974

16,698

(Decrease) increase in restricted cash

-

-

-

-

-

109

-5

93

Cash (used in) provided by investing activities

3,988

1,932

458

8,292

-38,290

-32,788

-11,018

-

Financing activities:
Proceeds from term loan and related warrants

-

-

6,000

-

-

-

-

-

Repayment of debt

-

-

10,042

-

-

-

-

-

Proceeds from sale of private placement, net of issuance costs

-15

38,756

-

-

-

-

-

-

Payment of financing costs

0

1,351

423

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-17,640

Proceeds from issuance of preferred stock, net of issuance costs

-

-

-

-

-

-

-

34,992

Proceeds from the issuance of common stock, net of issuance costs

26,688

0

-

-

-

51,733

32,414

4,039

Proceeds from option and warrant exercises

-

-

2

-

-

-

-

-

Cash acquired in connection with the Merger

0

33,316

-

-

-

-

-

-

Proceeds from convertible promissory notes

0

8,000

-

-

-

-

-

-

Repayment of debt and principal on finance lease

202

169

-

-

-

-

-

-

Purchase of redeemable noncontrolling interest

0

808

-

-

-

-

-

-

Proceeds from option and BSPCE warrant exercises

472

0

-

-

-

-

-

-

Issuances of common stock under benefit plans, net of withholding taxes paid

-

-

-

-

-

-21

0

-

Cash provided by (used in) financing activities

26,943

77,744

-4,463

54,148

125,386

51,712

32,414

-

Effect of foreign currency exchange rate changes on cash

33

118

-

-

-

-

-

-

Effect of foreign currency exchange rate changes on cash

-

-

19

-

-

-

-

-

Net decrease in cash, cash equivalents and restricted cash

-10,258

56,147

-24,326

-

-

-

-

-

Supplemental disclosure cash flow information
Cash paid for interest

-

-

213

-

-

-

-

-

Cash paid for taxes

0

4

-

-

-

-

-

-

Supplemental schedule of non-cash investing and financing activities:
Fair market value of securities issued in connection with Alizé asset purchase

-

-

63,002

-

-

-

-

-

Investment in OvaXon

-

-

-

-

-

-

1,500

-

Additions of property and equipment included in accounts payable and accrued liabilities

-

-

-

-

-

133

0

-

Conversion of convertible preferred stock into common stock

0

132,922

-

-

-

-

-

41,192

Reclassification of preferred stock warrant liability

0

99

-

-

-

-

-

-

Conversion of convertible promissory note into common stock

0

7,724

-

-

-

-

-

-

Exchange of noncontrolling interest

0

9,790

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

39,031

Net increase (decrease) in cash, cash equivalents and restricted cash

-

-

-

706

36,810

-11,664

3,302

10,235

Alizé acquisition costs included in accrued expenses

-

-

524

-

-

-

-

-

Financing costs in accounts payable and accrued expenses

197

15

-

-

-

-

-

-

Right-of-use assets acquired under operating leases

3,414

-

-

-

-

-

-

-